Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting Principles] net income of $727m for the first quarter of 2026 (Q1 2026), down 10% from $809m in Q1 2025. On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. GAAP diluted earnings per share (EPS) stood at $6.75 while non-GAAP diluted EPS grew 15% year-on-year to $9.47 from $8.22. Total revenue increased 19% year-on-year to $3.6bn from $3.02bn. Net product sales rose 8% to $1.53bn while collaboration revenue advanced 2 ...